Idiopathic Short Stature Clinical Trial
Official title:
A Randomized Controlled Trial Of The Use Of Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
When treating very short children in puberty we are time-limited, as sex hormones cause the growth plates to fuse and growth to end. Growth Hormone (GH), plus drugs that stop puberty, increase height potential, but leave children sexually infantile at a critical time in development. Human and animal data show that estrogen, in females and males, is a principal regulator of the fusion of the growth plate in puberty. Using aromatase inhibitors (AIs), which block testosterone to estrogen conversion, in boys with different growth disorders, we have shown that AIs may have beneficial effects enhancing height potential in growth-retarded males, without affecting their puberty. However, no direct comparison of the effect of AIs alone vs. conventional GH treatment has been done to date. This study will assess the effect of AIs alone, GH alone and combination treatment in enhancing height potential in adolescent boys with idiopathic short stature.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06382155 -
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
|
Phase 2 | |
Recruiting |
NCT05894876 -
A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
|
||
Completed |
NCT01246219 -
Short Stature Related Distress
|
Phase 4 | |
Completed |
NCT00965484 -
Genotropin Study Assessing Use of Injection Pen
|
Phase 3 | |
Completed |
NCT00710307 -
Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
|
||
Completed |
NCT01504802 -
Pharmacodynamics of CNP During Growth Hormone Treatment
|
N/A | |
Completed |
NCT00488124 -
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
|
Phase 2 | |
Withdrawn |
NCT01438801 -
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
|
Phase 4 | |
Recruiting |
NCT06309979 -
A Study to Assess Growth in Children With Idiopathic Short Stature
|
||
Terminated |
NCT00121875 -
Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature
|
Phase 4 | |
Not yet recruiting |
NCT05858606 -
Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients
|
N/A | |
Active, not recruiting |
NCT04020913 -
Skeletal Muscle Effects of GH in Boys
|
||
Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT02973061 -
The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
|
||
Completed |
NCT01778023 -
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
|
Phase 3 | |
Recruiting |
NCT01604395 -
Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
|
||
Active, not recruiting |
NCT00840944 -
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
|
Phase 4 | |
Completed |
NCT01070173 -
Ghrelin Levels in Children With Poor Growth
|
N/A | |
Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
Recruiting |
NCT04798690 -
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
|